Adalta Ltd - Asset Resilience Ratio

Latest as of June 2024: -3.70%

Adalta Ltd (1AD) has an Asset Resilience Ratio of -3.70% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 1AD strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

AU$-206.28K
≈ $-145.96K USD Cash + Short-term Investments

Total Assets

AU$5.57 Million
≈ $3.94 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2024)

This chart shows how Adalta Ltd's Asset Resilience Ratio has changed over time. See Adalta Ltd (1AD) balance sheet quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Adalta Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Adalta Ltd market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$-206.28K -3.7%
Total Liquid Assets AU$-206.28K -3.70%

Asset Resilience Insights

  • Limited Liquidity: Adalta Ltd maintains only -3.70% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Adalta Ltd Industry Peers by Asset Resilience Ratio

Compare Adalta Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Revolution Medicines Inc
NASDAQ:RVMD
Biotechnology 65.10%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Hugel Inc
KQ:145020
Biotechnology 29.57%
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Biotechnology 39.07%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
Biotechnology 2.30%
Absci Corp
NASDAQ:ABSI
Biotechnology 59.86%
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
Biotechnology 5.52%
Lifecome Biochemistry Co Ltd
SHE:002868
Biotechnology 4.69%

Annual Asset Resilience Ratio for Adalta Ltd (2017–2024)

The table below shows the annual Asset Resilience Ratio data for Adalta Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-06-30 -3.70% AU$-206.28K
≈ $-145.96K
AU$5.57 Million
≈ $3.94 Million
-52.44pp
2020-06-30 48.74% AU$3.37 Million
≈ $2.38 Million
AU$6.91 Million
≈ $4.89 Million
-10.94pp
2019-06-30 59.68% AU$5.56 Million
≈ $3.93 Million
AU$9.31 Million
≈ $6.59 Million
+7.73pp
2018-06-30 51.95% AU$2.31 Million
≈ $1.63 Million
AU$4.44 Million
≈ $3.14 Million
-24.99pp
2017-06-30 76.94% AU$6.22 Million
≈ $4.40 Million
AU$8.09 Million
≈ $5.72 Million
--
pp = percentage points

About Adalta Ltd

AU:1AD Australia Biotechnology
Market Cap
$5.41 Million
AU$7.65 Million AUD
Market Cap Rank
#28401 Global
#1514 in Australia
Share Price
AU$0.00
Change (1 day)
+0.00%
52-Week Range
AU$0.00 - AU$0.01
All Time High
AU$0.37
About

AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age… Read more